Moreover, some laboratory parameters (mainly C-reactive protein [CRP], lactate dehydrogenase [LDH], and neutrophils/lymphocytes ratio [NLR]) have shown potential as prognostic or even predictive markers of bevacizumab-based therapy in tumors relating to colorectal cancer, breast cancer, pancreatic cancer, renal cell cancer, glioblastoma, and ovarian cancer 12-17. This evidence concerns the gene CRP and renal cell adenocarcinoma.